E
Eupraxia Pharmaceuticals Inc.
EPRX
$3.27
-$0.0092-0.28%
E
Sell
3/25/2025Downgrade
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 3/25/2025 due to a large decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.04, earnings per share declined from -$0.1668 to -$0.4413, and EBIT declined 19.26% from -$6.27M to -$7.48M.
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 3/25/2025 due to a large decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.04, earnings per share declined from -$0.1668 to -$0.4413, and EBIT declined 19.26% from -$6.27M to -$7.48M.
D
Sell
11/5/2024Upgraded
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D- from E+ on 11/5/2024 due to an increase in the volatility index.
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D- from E+ on 11/5/2024 due to an increase in the volatility index.
E
Sell
10/21/2024Downgrade
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 10/21/2024 due to a decline in the volatility index.
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 10/21/2024 due to a decline in the volatility index.
D
Sell
9/4/2024Upgraded
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D- from E+ on 9/4/2024 due to an increase in the volatility index and total return index.
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D- from E+ on 9/4/2024 due to an increase in the volatility index and total return index.
E
Sell
8/19/2024Downgrade
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 8/19/2024 due to a decline in the total return index, volatility index and solvency index.
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 8/19/2024 due to a decline in the total return index, volatility index and solvency index.
D
Sell
5/31/2024Upgraded
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D- from E+ on 5/31/2024 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.01 to 1.95, debt to equity declined from 4.72 to 0.49, and EBIT increased 42.81% from -$11.7M to -$6.69M.
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D- from E+ on 5/31/2024 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.01 to 1.95, debt to equity declined from 4.72 to 0.49, and EBIT increased 42.81% from -$11.7M to -$6.69M.
E
Sell
5/24/2024Downgrade
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 5/24/2024 due to a major decline in the growth index, total return index and solvency index. Debt to equity increased from 0.91 to 4.72, earnings per share declined from -$0.1844 to -$0.3645, and EBIT declined 76.69% from -$6.62M to -$11.7M.
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E+ from D- on 5/24/2024 due to a major decline in the growth index, total return index and solvency index. Debt to equity increased from 0.91 to 4.72, earnings per share declined from -$0.1844 to -$0.3645, and EBIT declined 76.69% from -$6.62M to -$11.7M.
D
Sell
3/14/2023Downgrade
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D from D- on 02/23/2023.
Eupraxia Pharmaceuticals Inc. (EPRX) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index.
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
11/14/2022Upgraded
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D from D- on 11/14/2022 due to a major increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2399 to -$0.1667, and EBIT increased 22.54% from -$4.81M to -$3.73M.
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D from D- on 11/14/2022 due to a major increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2399 to -$0.1667, and EBIT increased 22.54% from -$4.81M to -$3.73M.
D
Sell
10/31/2022Upgraded
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D- from E+ on 10/31/2022 due to an increase in the volatility index and total return index.
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D- from E+ on 10/31/2022 due to an increase in the volatility index and total return index.
E
Sell
8/15/2022Downgrade
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to E+ from D- on 8/15/2022 due to a noticeable decline in the growth index, total return index and volatility index. EBIT declined 79.8% from -$2.68M to -$4.81M, and earnings per share declined from -$0.2046 to -$0.2399.
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to E+ from D- on 8/15/2022 due to a noticeable decline in the growth index, total return index and volatility index. EBIT declined 79.8% from -$2.68M to -$4.81M, and earnings per share declined from -$0.2046 to -$0.2399.
D
Sell
5/31/2022Upgraded
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index and valuation index.
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/13/2022Downgrade
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.46 to 0.55.
Eupraxia Pharmaceuticals Inc. (EPRXF) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.46 to 0.55.
D
Sell
5/1/2022Upgraded
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D- from E on 5/1/2022 due to an increase in the volatility index, total return index and efficiency index. Net income increased 25.25% from -$3.95M to -$2.95M.
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to D- from E on 5/1/2022 due to an increase in the volatility index, total return index and efficiency index. Net income increased 25.25% from -$3.95M to -$2.95M.
E
Sell
2/1/2022Upgraded
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to E from E- on 2/1/2022 due to an increase in the total return index.
Eupraxia Pharmaceuticals Inc. (EPRXF) was upgraded to E from E- on 2/1/2022 due to an increase in the total return index.
E
Sell
11/3/2021None
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E- from U on 11/03/2021.
Eupraxia Pharmaceuticals Inc. (EPRX) was downgraded to E- from U on 11/03/2021.
NASDAQ
04/02/2025 3:50PM Eastern
Quotes delayed
